Efficacy of prophylactic additional cranial irradiation and intrathecal chemotherapy for the prevention of CNS relapse after allogeneic hematopoietic SCT for childhood ALL. (12th May 2014)

• Record Type: Journal Article
• Authors: Fukano, Reiji; Nishimura, Miho; Ito, Nobuhiro; Nakashima, Kentaro; Kodama, Yuichi; Okamura, Jun; Inagaki, Jiro
• Is Part Of: Pediatric transplantation. Volume 18:Number 5(2014:Aug.)
• Page Start: 518
• Page End: 523
• Publication Date: 2014-05-12
• Subjects: Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.12276
• Languages: English
• ISSNs: 1397-3142

Abstract

<abstract abstract-type="main" id="petr12276-abs-0001"> <title>Abstract</title> <p>We evaluated the efficacy of CRT and IT chemotherapy, in addition to conditioning including TBI, for the prevention of CNS relapse, in allogeneic HSCT for childhood ALL. From January 1999 to December 2009, a total of 48 patients, without previous or presenting CNS involvement, underwent HSCT for ALL. All patients received myeloablative conditioning including TBI of 12 or 13.2 Gy and IT chemotherapy twice between days −10 and −2 prior to HSCT. Twenty‐five patients received CRT prior to TBI (CRT+), and 23 patients did not (CRT−). CRT+ and CRT− patients had a seven‐yr EFS rate of 40.0 ± 9.8% and 41.7 ± 10.6%, respectively (p = 0.8252). The seven‐yr relapse rates for CRT+ and CRT− patients were 45.0 ± 11.2% and 38.4 ± 11.6%, respectively (p = 0.7460). CNS relapses were evident in 1 (4.0%) CRT+ patient and 1 (4.4%) CRT− patient (p = 1.000). There were no significant differences in EFS and the probability of CNS relapse between CRT+ and CRT− patients. These results demonstrate that CRT and IT chemotherapy, in addition to conditioning chemotherapy, may not be necessary in childhood ALL patients without previous or presenting CNS involvement.</p> </abstract>